The “showdown” at the American Society of Clinical Oncology (ASCO) meeting foreseen by one analyst between breast cancer drugs from Gilead Sciences Inc. and Astrazeneca plc with partner Daiichi Sankyo Co. Ltd. didn’t quite materialize.